HAVCR2 and nasopharyngeal carcinoma: Although therapeutic targeting to HAVCR2 and LAG3 is currently not as mature as to PD-1, we must pay attention that the NPC microenvironment is unique and complicated, which means that we cannot directly adapt a developed therapeutics from other malignancies into NPC treatment.